Show simple item record

dc.contributor.authorZhou, Ye
dc.date.accessioned2011-08-31T16:53:50Z
dc.date.available2011-08-31T16:53:50Z
dc.date.issued2011-08-31
dc.date.submittedJuly 2011
dc.identifier.urihttp://hdl.handle.net/1928/13191
dc.description.abstractc-myb encodes a transcription factor that is essential for hematopoiesis and for normal development of other tissues. There is ample evidence showing the activated alleles of c-myb gene can induce leukemias in several animal species. However, there was no clear evidence showing that c-myb could be oncogenic in human cancers until recent studies revealed that the human c-myb locus is subjected to chromosomal rearrangement in some pediatric T-ALL and adenoid cystic carcinoma (ACC) patient samples. The c-myb gene contains 15 constant exons and 6 alternative exons and can undergo extensive alternative splicing. These alternatively spliced variants encode variant Myb proteins sharing the same DNA binding domain but distinct C-terminal domains. Evidence suggests that despite their identical DNA binding domains, these c-Myb variant proteins have unique transcriptional activities: the differences in the proteins allow the proteins to regulate different sets of target genes. Most importantly, some of the variants have C-terminal deletions that resemble the deletions in v-Myb, the oncogenic variant of c-Myb that can induce acute leukemias in chickens and mice. Previous studies showed that c-myb alternative splicing is tightly regulated during hematopoiesis. The profiles of c-myb alternative splicing in some leukemias are different from the profiles in normal bone marrow samples. We hypothesized that c-myb is a unique oncogene that is activated by alternative splicing in leukemias, resulting in the production of variant forms of c-Myb protein that contribute to hematopoietic cell transformation and the development of leukemia. To evaluate the clinical significance of c-myb alternative splicing and find out its correlation with leukemia, profiling of c-myb alternative splicing in a cohort of leukemia patient samples is needed. We developed a single-molecule exontyping method to characterize the alternative splicing of c-myb RNAs in a small cohort of pediatric pre-B-ALL samples and correlated the level or the pattern of c-myb splice variants with survival time of these patients. We detected that c-myb alternative splicing is more complex and more prevalent in leukemia patients than in normal cells. Furthermore, some splice variants encoding Myb proteins with truncations in the C-terminal domain are correlated with poor survival. We further explored the possibility of adapting high-throughput low-cost Next-Generation Sequencing methods to analyze c-myb alternative splicing at a large scale. We conclude that de-regulated c-myb alternative splicing could be an important contributor to the development of leukemia and that the analysis of c-myb splicing could provide a unique and novel approach of classifying leukemias, which is distinct from analyses performed with other technologies, such as microarray assays of gene expression.en_US
dc.description.sponsorshipNIHen_US
dc.language.isoen_USen_US
dc.subjectc-myben_US
dc.subjectalternative splicingen_US
dc.subjectbiomarkeren_US
dc.subjectnext-generation sequencingen_US
dc.subjectsingle molecule assayen_US
dc.titlec-myb alternative splicing: a novel biomarker in leukemiaen_US
dc.typeDissertationen_US
dc.description.degreeBiomedical Scienceen_US
dc.description.levelDoctoralen_US
dc.description.departmentUniversity of New Mexico. Biomedical Sciences Graduate Programen_US
dc.description.advisorNess, Scott
dc.description.committee-memberOzben, Michelle
dc.description.committee-memberHathaway, Helen
dc.description.committee-memberEdwards, Jeremy
dc.description.committee-memberNess, Scott
dc.data.json{ "@context": { "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#", "rdfs": "http://www.w3.org/2000/01/rdf-schema#", "xsd": "http://www.w3.org/2001/XMLSchema#" }, "@graph": [ { "@id": "http://wikidata.dbpedia.org/resource/Q1129238", "@type": "http://schema.org/Intangible" }, { "@id": "http://wikidata.dbpedia.org/resource/Q864574", "@type": "http://schema.org/Intangible" }, { "@id": "http://54.191.234.158/entities/resource/next-generation-sequencing", "@type": "http://schema.org/Intangible" }, { "@id": "http://hdl.handle.net/1928/13191", "@type": "http://schema.org/CreativeWork", "http://purl.org/montana-state/library/associatedDepartment": { "@id": "http://54.191.234.158/entities/resource/University_of_New_Mexico.__Biomedical_Sciences_Graduate_Program" }, "http://purl.org/montana-state/library/degreeGrantedForCompletion": "Biomedical Science", "http://purl.org/montana-state/library/hasEtdCommitee": { "@id": "http://54.191.234.158/entities/resource/1928/13191" }, "http://purl.org/montana-state/library/reviewedBy": { "@id": "http://54.191.234.158/entities/resource/Committee/1928/13191" }, "http://schema.org/about": [ { "@id": "http://54.191.234.158/entities/resource/single-molecule-assay" }, { "@id": "http://54.191.234.158/entities/resource/next-generation-sequencing" }, { "@id": "http://54.191.234.158/entities/resource/alternative_splicing" }, { "@id": "http://wikidata.dbpedia.org/resource/Q1129238" }, { "@id": "http://54.191.234.158/entities/resource/c-myb" }, { "@id": "http://54.191.234.158/entities/resource/biomarker" }, { "@id": "http://54.191.234.158/entities/resource/single_molecule_assay" }, { "@id": "http://54.191.234.158/entities/resource/next-generation_sequencing" }, { "@id": "http://wikidata.dbpedia.org/resource/Q864574" } ], "http://schema.org/author": { "@id": "http://54.191.234.158/entities/resource/Zhou_Ye" }, "http://schema.org/dateCreated": "July 2011", "http://schema.org/datePublished": "2011-08-31", "http://schema.org/description": "c-myb encodes a transcription factor that is essential for hematopoiesis and for normal development of other tissues. There is ample evidence showing the activated alleles of c-myb gene can induce leukemias in several animal species. However, there was no clear evidence showing that c-myb could be oncogenic in human cancers until recent studies revealed that the human c-myb locus is subjected to chromosomal rearrangement in some pediatric T-ALL and adenoid cystic carcinoma (ACC) patient samples. The c-myb gene contains 15 constant exons and 6 alternative exons and can undergo extensive alternative splicing. These alternatively spliced variants encode variant Myb proteins sharing the same DNA binding domain but distinct C-terminal domains. Evidence suggests that despite their identical DNA binding domains, these c-Myb variant proteins have unique transcriptional activities: the differences in the proteins allow the proteins to regulate different sets of target genes. Most importantly, some of the variants have C-terminal deletions that resemble the deletions in v-Myb, the oncogenic variant of c-Myb that can induce acute leukemias in chickens and mice. Previous studies showed that c-myb alternative splicing is tightly regulated during hematopoiesis. The profiles of c-myb alternative splicing in some leukemias are different from the profiles in normal bone marrow samples. We hypothesized that c-myb is a unique oncogene that is activated by alternative splicing in leukemias, resulting in the production of variant forms of c-Myb protein that contribute to hematopoietic cell transformation and the development of leukemia. To evaluate the clinical significance of c-myb alternative splicing and find out its correlation with leukemia, profiling of c-myb alternative splicing in a cohort of leukemia patient samples is needed. We developed a single-molecule exontyping method to characterize the alternative splicing of c-myb RNAs in a small cohort of pediatric pre-B-ALL samples and correlated the level or the pattern of c-myb splice variants with survival time of these patients. We detected that c-myb alternative splicing is more complex and more prevalent in leukemia patients than in normal cells. Furthermore, some splice variants encoding Myb proteins with truncations in the C-terminal domain are correlated with poor survival. We further explored the possibility of adapting high-throughput low-cost Next-Generation Sequencing methods to analyze c-myb alternative splicing at a large scale. We conclude that de-regulated c-myb alternative splicing could be an important contributor to the development of leukemia and that the analysis of c-myb splicing could provide a unique and novel approach of classifying leukemias, which is distinct from analyses performed with other technologies, such as microarray assays of gene expression.", "http://schema.org/inLanguage": "en_US", "http://schema.org/isPartOf": [ { "@id": "http://hdl.handle.net/1928/6682" }, { "@id": "http://hdl.handle.net/1928/10575" } ], "http://schema.org/name": "c-myb alternative splicing: a novel biomarker in leukemia" }, { "@id": "http://54.191.234.158/entities/resource/single-molecule-assay", "@type": "http://schema.org/Intangible" }, { "@id": "http://54.191.234.158/entities/resource/Zhou_Ye", "@type": "http://schema.org/Person" }, { "@id": "http://54.191.234.158/entities/resource/single_molecule_assay", "@type": "http://schema.org/Intangible" }, { "@id": "http://54.191.234.158/entities/resource/c-myb", "@type": "http://schema.org/Intangible" }, { "@id": "http://54.191.234.158/entities/resource/next-generation_sequencing", "@type": "http://schema.org/Intangible" }, { "@id": "http://54.191.234.158/entities/resource/alternative_splicing", "@type": "http://schema.org/Intangible" }, { "@id": "http://hdl.handle.net/1928/6682", "@type": "http://schema.org/WebSite" }, { "@id": "http://hdl.handle.net/1928/10575", "@type": "http://schema.org/WebSite" }, { "@id": "http://54.191.234.158/entities/resource/biomarker", "@type": "http://schema.org/Intangible" } ]}


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record